Wynne Weston-Davies
Keine laufenden Positionen mehr
Profil
Wynne Weston-Davies worked as a Medical Director at Evolutec Group Plc, Volution Immuno Pharmaceuticals SA, and Akari Therapeutics Plc.
He also worked as a Medical Director at Varleigh Immuno Pharmaceuticals Uk Ltd.
from 2009 to 2014.
Ehemalige bekannte Positionen von Wynne Weston-Davies
Unternehmen | Position | Ende |
---|---|---|
Varleigh Immuno Pharmaceuticals Uk Ltd. | Chief Tech/Sci/R&D Officer | 01.01.2014 |
Evolutec Group Plc
Evolutec Group Plc BiotechnologyHealth Technology Evolutec Group Plc is an biopharmaceutical company, which discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. It was founded in1998 and headquartered in Oxford, United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Volution Immuno Pharmaceuticals SA
Volution Immuno Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Part of Akari Therapeutics Plc, Volution Immuno Pharmaceuticals SA is a Swiss company that develops anti-complement and anti-inflammatory molecules to treat orphan conditions in the autoimmune and inflammatory diseases sectors. The private company is based in Geneva, Switzerland. The company was founded by Raymond Prudo-Chlebosz, who has been the CEO since incorporation. Volution Immuno Pharmaceuticals was acquired by Celsus Therapeutics Plc from RPC Pharma Ltd. on September 18, 2015 for $146.72 million. | Chief Tech/Sci/R&D Officer | - |
AKARI THERAPEUTICS, PLC | Chief Tech/Sci/R&D Officer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AKARI THERAPEUTICS, PLC | Health Technology |
Private Unternehmen | 3 |
---|---|
Evolutec Group Plc
Evolutec Group Plc BiotechnologyHealth Technology Evolutec Group Plc is an biopharmaceutical company, which discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. It was founded in1998 and headquartered in Oxford, United Kingdom. | Health Technology |
Volution Immuno Pharmaceuticals SA
Volution Immuno Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Part of Akari Therapeutics Plc, Volution Immuno Pharmaceuticals SA is a Swiss company that develops anti-complement and anti-inflammatory molecules to treat orphan conditions in the autoimmune and inflammatory diseases sectors. The private company is based in Geneva, Switzerland. The company was founded by Raymond Prudo-Chlebosz, who has been the CEO since incorporation. Volution Immuno Pharmaceuticals was acquired by Celsus Therapeutics Plc from RPC Pharma Ltd. on September 18, 2015 for $146.72 million. | Health Technology |
Varleigh Immuno Pharmaceuticals Uk Ltd. |